Lipocine to Present at 29th Annual ROTH Conference
March 06, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
February 15, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men’s and...
Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
January 09, 2017 07:00 ET
|
Lipocine, Inc.
Critical Phase 3 study design input received from U.S. Food and Drug Administration (“FDA”): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator...
Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate
January 05, 2017 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility (“DF”) study in addition to...
Lipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate
December 05, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced it plans to initiate a dosing validation study after receiving...
Lipocine Announces Financial and Operational Results for the Third Quarter of 2016
November 08, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended September...
Lipocine Announces Issuance of US Patent 9,480,690
November 07, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today reported the United States Patent and Trademark Office (“USPTO”) issued...
Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application
October 17, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and...
Lipocine Wins Dismissal of Patent Infringement Lawsuit Related to LPCN 1021
October 07, 2016 14:32 ET
|
Lipocine, Inc.
SALT LAKE CITY, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that U.S. District Court in Delaware granted our motion to dismiss...
Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy
September 26, 2016 08:00 ET
|
Lipocine, Inc.
Once-daily dose identified for the pivotal Phase 3 studyWell tolerated with no drug-related severe or serious adverse events reported SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Lipocine...